A Study to Assess Symptom Burden in Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Aranesp®

Amgen

Status and phase

Completed

Phase 4

Conditions

Anemia

Treatments

Drug: Aranesp

Study type

Interventional

Funder types

Industry

Identifiers

NCT00117117

20020132

Details and patient eligibility

About

The purpose of this trial is to prospectively assess the relationship between changes in hemoglobin (hgb) and changes in symptom burden associated with anemia in cancer patients receiving chemotherapy supported with Aranesp®.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Subjects with nonmyeloid malignancy(ies)
Anemia (hgb less than or equal to 11.0 g/dL) due to cancer and chemotherapy

Exclusion criteria

Subjects with acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), myelodysplastic syndromes (MDS)
Unstable cardiac disease or anemia due to other causes